Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Neuroglee Therapeutics

Explore full profile

Discovers, develops, and commercializes software as medical treatment for patients with neurodegenerative diseases

Singapore, SingaporeFounded 2020Health Tech & Medtech
Valuation $0–100M Latest valuation · 2021
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Neuroglee Therapeutics and the history behind them.

About Neuroglee Therapeutics

Neuroglee is a healthcare startup that operates in the digital health sector, specifically focusing on cognitive care. The company has developed a platform that measures cognitive functioning and well-being of patients throughout their care journey. The platform is designed to serve patients with cognitive impairments, such as those diagnosed with mild cognitive impairment (MCI), and their families.

Read full description

Neuroglee's business model revolves around providing personalized care plans to help patients form healthy habits and develop practical skills to protect brain health and maintain independence. The company's clinical team provides continuous support, recommends personalized changes to the patient's program, and identifies health concerns early. This integrated approach bridges the gap between the patient's local healthcare team and their home, ensuring optimal care.

The company's digital solutions connect patients and families throughout the care journey with support communities, resources, and exercises to manage the patient's condition. The goal is to slow neurocognitive decline and promote independence. For instance, a patient like Barbara, diagnosed with MCI, would regularly participate in Neuroglee's software-based cognitive training program. The company monitors her cognitive performance, reports improvements to her care team, and recommends educational material to help her stay on track.

Neuroglee generates revenue by partnering with healthcare providers and institutions, like the Mayo Clinic, to digitize and integrate their cognitive care programs into Neuroglee's platform. This allows healthcare providers to offer their patients a comprehensive, digital cognitive care solution.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2020
Headquarters
Singapore, Singapore
Employees
9
Open positions
None listed
Dealroom signal
58.2/100
Industry
Health
Sub-industry
Health Platform
Sector
Health Tech & Medtech, Disability tech, Digital Therapeutics, Tech for Biotech and Pharma, Tech for Hospitals and Clinics, Tech for Patients, Hard Tech
Technology
Artificial Intelligence, Machine Learning
Business model
Manufacturing
Client focus
b2b

Latest news

Press, funding announcements and product moves mentioning Neuroglee Therapeutics.

See all news

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AEquity / VC Sep 2021 $10M $40M Ramen Singh · EDBI · Eisai · Wendou Liu
SEEDEquity / VC Dec 2020 $2.3M $9.2M Eisai
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Neuroglee Therapeutics website traffic

Latest recorded traffic for Neuroglee Therapeutics is 950 monthly website visits, down 2.1% over the last three months. Neuroglee Therapeutics's team declined 30.8% over the past year.

Latest monthly visits950 3-month web change-2.1% 1-year team growth-30.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Eisai

Series A4 investors entered at this stage

  • EDBI
  • Openspace Ventures
  • Ramen Singh
  • Wendou Liu

Other known investors2 additional known investors

  • 2050 Capital
  • Fernand Lendoye
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States83.3%
🇮🇳 India16.7%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Neuroglee Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Neuroglee Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.